GlaxoSmithKline receives positive EU opinion for eltrombopag
30 December 2009 00:00 in Pharmaceutical Company Product News
GlaxoSmithKline has revealed that the European Medicines Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Revolade (eltrombopag) ? a drug intended to treat reduced platelet count, or thrombocytopenia, in adults with the blood disorder chronic immune thrombocytopenic purpura (ITP).
Marketing authorisation has been granted by the CHMP for eltrombopag in the EU for the treatment of ITP in adults who have had their spleen removed and later fail to respond to corticosteroids and immunoglobulins therapies.
The oral compound may also be considered as a second-line therapy for adult patients where surgery to remove their spleen is contraindicated, the firm added.
Paolo Paoletti, senior vice-president and global head of oncology research and development at GlaxoSmithKline, commented: "Eltrombopag is an innovative treatment for thrombocytopenia in patients with chronic ITP. This once-a-day tablet is able to stimulate platelet production and reduce the risk of bleeding in a difficult-to-treat disease."
Earlier this week, GlaxoSmithKline announced that it will work alongside NanoBio to develop the latter firm's over-the-counter cold sore treatment NB-001.
Other news stories from 30/12/2009
Read more in the Zenopa News Archive
How this news is generated
Story collated for Zenopa by the Adfero News Agency